^(18)F-FDG PET/CT在朗格汉斯细胞组织细胞增生症中的应用价值  

Application value of ^(18)F-FDG PET /CT in patients with Langerhans' cell histiocytosis

作　　者：仲燕燕[1] 秦朝军[2] 黄盛才[2] 颜李梅[2] 

机构地区：[1]广西医科大学研究生学院 [2]广西医科大学第一附属医院PET/CT部,南宁市530021

出　　处：《微创医学》2014年第1期28-30,69,共4页Journal of Minimally Invasive Medicine

基　　金：广西自然科学基金(合同号:桂科自0640124)

摘　　要：目的探讨18F-FDG PET/CT显像学特征在朗格汉斯细胞组织细胞增生症(LCH)分型及疗效评价中的价值。方法回顾性分析经病理证实的18例朗格汉斯细胞组织细胞增生症患者的18F-FDG PET/CT显像资料,分别记录病灶的结构特征及葡萄糖代谢特征。结果 9例患者为EGB组,9例患者为LS组。EGB组患者化疗前的SUVmax值(7.4±0.5)明显高于LS组SUVmax(2.4±1.4)。11例患者化疗前后均行PET/CT检查,化疗前SUVmax(4.5±2.7),化疗后SUVmax(1.4±1.1),两组比较(t=5.044,P=0.001<0.05),差异有统计学意义。结论化疗后SUVmax明显下降,PET/CT全身显像对朗格汉斯细胞组织细胞增生症的分型及化疗疗效评价有重要的作用。Objective To explore the radiographic characteristics of PET-CT in patients with Langerhans′ cell histiocytosis（LCH）. Methods The radiographic data of PET-CT of 18 patients with LCH were analyzed retrospectively, and structural and glucose metabolic features of the lesions were recorded. Results Patients were divided into EGB group or LS group, each included 9 patients. SUVmax of LS group before chemotherapy was obviously higher than that of EGB group （7.4±0.5 vs 2.4±1.4, P=0.005）.Among 18 patients, 11 patients underwent PET-CT imaging test both before and after chemotherapy, and their pretreatment SUVmax was significantly higher than that of post treatment（4.5±2.7 vs 1.4±1.1,P=0.001）. Conclusion After chemotherapy, SUVmax of patients with LCH greatly decreases. Whole body image of PET/CT plays an important role in the grouping and the chemotherapeutic effectiveness evaluation of LCH.

关 键 词：18氟-脱氧葡萄糖 正电子发射计算机断层显像 朗格汉斯细胞组织细胞增生症 诊断 评价 

分 类 号：R55[医药卫生—血液循环系统疾病]